#Bayer (BAYRY) - Prohost Biotech

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease

Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 – Bayer AG (BAYRY) and its subsidiary firm BlueRock Therapeutics LP announced positive top-line results from...

P

Prohost Biotech

Jun 29, 2023

CureVac N.V.

Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. ( CVAC ) , when the company announced business updates and financi...

P

Prohost Biotech

Apr 18, 2021

Compugen: Why the Great Expectations from this Firm

The Compugen Story For those who are still asking about the value of Compugen’s ( CGEN ) discoveries our answer is that the best story written about this firm is its own autobiography. We believe Co...

P

Prohost Biotech

Jan 22, 2021

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen ( CGEN ) and AstraZeneca ( AZN ) entered into an agreement by which Compugen provided an exclusive license to AstraZeneca f...

P

Prohost Biotech

Dec 23, 2020

CRISPR Therapeutics - Professor Emmanuelle Charpentier - Gene Editing and the Future of Humanity

CRISPR Therapeutics Dr. Emmanuelle Charpentier, Co-Founder CRISPR Therapeutics ( CRSP ) announced on October 7, 2020 that Dr. Emmanuelle Charpentier has been awarded the 2020 Nobel Prize in Chemistry...

P

Prohost Biotech

Nov 6, 2020

Compugen: A Stock To Keep

Compugen Compugen ( CGEN ) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’...

P

Prohost Biotech

Aug 3, 2020

What Was Seen and What Was Ignored

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History and self-experiences enabled investors to expect and swallow biased reactions following the announcements...

P

Prohost Biotech

Oct 29, 2019

The Week in Review #37

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation by Bayer demonstrated improvement in the treatment of non-metastatic castration-...

P

Prohost Biotech

Feb 19, 2019

1m

2

News & Comments

Loxo Oncology product Vitrakvi® has been granted FDA approval. The real meaning of the approval

As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) approved Loxo Oncology's (LOXO) Vitrakvi® (larotrectinib), the first oral TRK inhibitor fo...

P

Prohost Biotech

Nov 27, 2018

Prohost Letter #403 Part 2

Prohost Letter #403 Part 2 Continued From Wednesday Instead of continuing yesterday article about Agenus, we decided to post it all so that the reader can find it in one place. Important changes and a...

P

Prohost Biotech

Dec 16, 2016

1m

0

News & Comments

Another CRISPR Gene Editing Company Decided to Go Public. What's Investors' Decision?

Another gene editing firm, CRISPR Therapeutics decided to become publicly traded. On Friday, the private firm filed with the SEC planning for a $90 million initial public offering (IPO). CRISPR Thera...

P

Prohost Biotech

Sep 13, 2016

Learning from Pfizer Acquisition. Regeneron to Fight Zika and More

Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors to know what Pfizer is after with regard to this acquisition so that investors could sense the current d...

P

Prohost Biotech

Aug 23, 2016

Prohost Letter #390

Prohost Letter #390 COMPANIES USING CRISPR GENE EDITING TOOLS - The Firms Launched with CRISPR Patents Either Pending or Disputed! What Does This Mean? What are these Firms’ Priorities? But First: A...

P

Prohost Biotech

Jan 15, 2016

Prohost Letter #356

...

P

Prohost Biotech

Feb 23, 2014

1m

16

News & Comments

Two Small Great Biotechs Underestimated by the Market

Seattle Genetics’ (SGEN) and ImmunoGen’s (IMGN) conjugated monoclonal antibody therapeutics for cancer are increasingly validating their superior safety and efficacy over other cancer products that ar...

P

Prohost Biotech

Jun 25, 2013

Wednesday's Highlights ~ January 18, 2012: We Selected the Following News

PROLOR (PBTH) announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The...

P

Prohost Biotech

Jan 18, 2012

1m

2